Estudos de custo sobre terapia dialítica no mundo: uma revisão sistemática e uma abordagem histórica

  • Alyne Schreider Pós-Graduação em Saúde, Universidade Federal de Juiz de Fora
  • Manoel Francisco de Souza Neto Estatística da Universidade Federal de Juiz de Fora
  • Juliana Paula Pereira Pós-Graduação em Saúde da Universidade Federal de Juiz de Fora
  • Natalia Maria da Silva Fernandes Departmento de Clínica Médica, Faculdade de Medicina, 4- Departmento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Juiz de Fora
Palavras-chave: Custos e Análise de Custo, Gastos em Saúde, Diálise Peritoneal, Diálise Renal

Resumo

Introdução: A doença renal afeta 850 milhões de pessoas no mundo e é uma das principais contribuintes para a carga global de doenças não transmissíveis (DNT). Projeta-se que até 2040 seja a quinta causa de anos de vida perdidos. Objetivo: Avaliar onde (geograficamente) e como estão sendo feitos os estudos de custo em terapia dialítica no mundo. Material e métodos: Foi realizada nos dias 26/06/2017, 10/07/2017 e 30/09/2018 uma busca com os unitermos “cost and cost analysis”, ”health expenditures” and “peritoneal dialysis”, os mesmos unitermos e “renal dialysis” nas bases Pubmed, Scielo e EmBase e foram encontrados 1796 artigos, destes foram selecionados 124. Acrescentou-se análise no Google Acadêmico. Ao final, analisou-se 125 artigos. Os critérios de inclusão dos artigos foram terem como escopo do estudo o custo, utilizando metodologias diversas como custo, custo total, custo efetividade, custo utilidade, custo benefício, custo minimização, gasto, impacto econômico. A perspectiva poderia ser do pagador e do prestador de serviço. Resultados: Observou-se um maior número de publicações a partir do ano 2000. Com relação ao desenho dos estudos, a maioria apresentou metodologia de difícil reprodutibilidade, utilizando conceitos variados e métodos diversos. Há uma grande variabilidade do custo entre os países e até mesmo entre os centros de diálise. Em linhas gerais, em países de alta renda, a DPAC (diálise peritoneal ambulatorial contínua) e a DPA (diálise peritoneal automatizada) apresentam menor custo quando comparadas à HD (hemodiálise). No Brasil a maioria dos estudos mostra HD apresentando menor custo que DPAC e DPA. Os desenhos são diversos e mostram, em geral, a perspectiva do pagador.   Conclusão: Estudos de custos são recentes na literatura, incluem métodos diversos e a descrição dos resultados não é padronizada. Esperamos progredir para uma discussão da saúde baseada em valor.

Referências

International Society of Nephrology. ISN, supported by ERA-EDTA and ASN calls for kidney disease inclusion member states UHC plan [Internet]. 2019. [Citado em 2019/07/02] Disponível em: https://www.theisn.org/news/item/3428-theisnsupported-by-theera-edtaand-the-asnwelcomes-the-political-declaration-on-uhc.

Instituto Brasileiro de Geografia e Estatística (BR). Sinopse do Censo Demográfico Brasileiro: 2010 [Internet]. Rio de Janeiro: IBGE; 2011. [Citado 2017/07/02] Disponível em: https://biblioteca.ibge.gov.br/visualizacao/livros/liv49230.pdf.

International Society of Nephrology. Chronic Kidney Disease [Internet]. 2019. [Citado em 2019/08/02] Disponível em: www.theisn.org/global-atlas.

Richardson JA, Philbin PE, Herron GR. Low-cost system of peritoneal dialysis. Br Med J. 1968; 4(5633):757-9. doi: 10.1136/bmj.4.5633.757-a.

Mani MK, Raibagi MH, Dingankar AD. The economics of peritoneal dialysis: a cost–efficiency study. Nephron. 1976; 17(2):130-5. doi: 10.1159/000180718.

Rae A, Craig P, Miles G. Home dialysis: its costs and problems. Can Med Assoc J. 1972; 106(12):1305.

Sesso R, Eisenberg JM, Stabile C, Draibe S, Ajzen H, Ramos O. Cost-effectiveness analysis of the treatment of end-stage renal disease in Brazil. Int J Technol Assess Health Care. 1990; 6(1):107-14. doi: 10.1017 / s0266462300008965

Croxson BE, Ashton T. A cost effectiveness analysis of the treatment of end stage renal failure. N Z Med J. 1990; 103(888):171-4.

Newman LN, Hanslik TM, Tessman M. Cost-effective atomated peritoneal dialysis for patients with average to low transport. Anna J. 1994; 21(5):271-3.

Chanut C, Barnouin F, Benech JM, Bouvier P, Briat C, Hecht M et al. Assessment of costs of health insurance, substitution therapy in chronic renal insufficiency. Ver Epidemiol Sante Publique. 1991; 39(4):353-64.

Dubois JP. Legal and economics aspects of peritoneal dialysis. Nephrologie. 1995; 16(1):145-50.

Lebrun T, Marissal JP, Sailly JC. Measuring the economic impact of ambulatory dialysis: the case of continuous ambulatory peritoneal dialysis. Rev Epidemiol Sante Publique. 1997; 45(6): 493-507.

Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med. 1995; 18(6):455-64.

Weinstein MC, Obrien B, Hornberger J, Jackson J, Johannesson M, McCabe C et al. Principles of good practice for decisison therapy analytic modeling in health-care evaluation: report of the ISPOR task force on good research practice-modeling studies. Value Health. 2003; 6(1):9-17. doi: 10.46/j.1524-4733.2003.00234.

Naidas OD, Chan-Licuanan KR, Velasco VP, Dalay CV, Bayog DV, Rosete-liquete RM. Cost effectiveness analysis of alternative treatments of end- stage renal disease: Philippine experience. Transplant Proc. 1998; 30(7):3116. doi: 10.1016/s0041-1345(98)00956-7.

Lim TO, Lim YN, Wong HS, Ahmad G, Singam TS, Morad Z et al. Cost effectiveness evaluation of the Ministry of health Malaysia dialysis programme. Med J malaysia. 1999; 54(4):442-52.

Li PK, Chow KM. The cost barrier to peritoneal dialysis in the developing world an Asian perspective. Perit Dial Int. 2001; 3:S307-13.

Hooi LS, Lim TO, Goh A, Wong HS, Tan CC, Ahmad G et al. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia.Nephrology(carlton). 2005; 10(1):25-32. doi: 10.1111/j.1440-1797.2005.00360.

Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evalution of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health. 10(1):61-72. doi: 10.1111/j.1524-4733.2006.00145.

Kao TW , Chang YY , Chen PC , Hsu CC , Chang YK , Chang YH et al. Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan. Perit Dial Int. 2013; 33(6):671-8. doi: 10.3747/pdi.2012.00081.

Yoshesd NV, Georgi A, Milly M, Rajan R, Yuvaram NV. Na Indian model for cost-effective with minimal man power and economic resources. Nephrology Dialysis Trnasplantation. 2011; 26(10):3089-91. doi: https://doi.org/10.1093/ndt/gfr353.

Su CY, Lu XH, Wang T. Influence of diferente payment schemes on the cllinical outcome in peritoneal dialysis patients. Perit Dial Int. 2016; 36(2):205-12. doi: 10.3747/pdi.2014.00132

Lo WK. What factors contribute to differences in the practice of peritoneal dialysis between Asian countries and the west? Perit Dial Int. 2002; 22(2):249-57.

Yang JY, Chen L, Chao CT, Peng YS, Chiang CK, Kao TW et al. Compative study of outcomes among patients with polycystic kidney disease on hemodialysis and peritoneal dialysis. Sci Rep. 2015; 5:12816. doi: 10.1038/srep12816.

Tang CH, Wu YT, Huang SY, Chen HH, Wu MJ, Hsu BG et al. Economics costs of automated and continuous ambulatory peritoneal dialysis in Taiwan: a combined survey and retrospective cohort analysis. BMJ Open. 2017; 7(3):e15067. doi: 10.1136/bmjopen-2016-015067.

Bruns FJ, Seddon P, Saul M, Zeidel ML. The cost of caring for end-estage kidney disease patients: an analysis based on hospital financial transaction records. J Am Soc Nephrol. 1998; 9(5):884-90.

Holley JL, McGuirl K, Smith S, Caswell N. Reducing a peritoneal dialysis program’s cost by chaging from a verdor-provided to a program-provided system for general medical supplies: significant savings in CCPD. Am J Kidney Dis. 1998; 31(4):662-5. doi: 10.1053/ajkd.1998.v31.pm9531183.

Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002; 40(3):611-22. doi: 10.1053/ajkd.2002.34924.

Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Healtn economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002; 22(5):417-30. doi: 10.1177/027298902236927.

Neil N, Guest S, Wong G, Portoghese L, Bhattacharyya SK, Gehr t et al. The financial implications for medicare of greater use of peritoneal dialysis. Clin Ther. 2009; 31(4):880-8. doi: 10.1016/j.clinthera.2009.04.004.

Berger A, Edelsberg J, Inglese GW, Bhattacharyya SK, Oster G. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease. Am J Manag care. 2009; 18(8):509-18.

Liu FX, Walton SM, Leipold R, Isbell D, Golper TA. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system. Perit Dial Int. 2014; 34(7):749-57. doi: 10.3747/pdi.2013.00305.

Liu FX, Ghaffari A, Dhatt H, Kumar V, Balsera C, Wallace E et al. Economic evaluation of urgente start peritoneal dialysis versus urgente start hemodialysis in the United States. Medicine. 2014; 93(28):e293. Doi: 10.1097/MD.0000000000000293.

Benain JP, Faller B, Briat C, Jacquelinet C, Brami M, Aoustin M et al. Cost of dialysis in France. Nephrol Ther. 2007; 3(3):96-106. doi: 0.1016/j.nephro.2007.03.001.

Chanliau J, Kessler M . Peritoneal dialysis for ESRD patients: financial aspects. Nephrol Ther. 2011; 7(1):32-7. doi: 10.1016/j.nephro.2010.10.004.

Rodrigues A. Cost benefits of peritoneal dialysis in specific groups of patients. Contrib Nephrol. 2009; 163:285-291. doi: 10.1159/000223812.

Arrieta J, Rodríguez-Carmona A, Remón C, Pérez-Fontán M, Ortega F, Sánchez Tomero JA et al. Peritoneal dialysis is the best cost-effective alternative for maintaining dialysis treatment. Nefrologia. 2011; 31(5):505-13. doi: 10.3265/Nefrologia.pre2011.Jul.11103.

Lamas Barreiro JM, Alonso Suárez M, Saavedra Alonso JA, Gándara Martínez A. Costs and added value of haemodialysis and peritoneal dialysis outsourcing agreements. Nefrologia. 2011; 31(6):656-63. doi: 10.3265/Nefrologia.pre2011.

Rocha MJ, Ferreira S, Martins LS, Almeida H, Dias G, Pedroso S et al. Cost analysis of renal replacement therapy by transplant in a system of bundled payment of dialysis. Clin Transplant. 2012; 26(4):529-31. doi: 10.1111/j.1399-0012.2011.01571.

Coentrão LA, Araújo CS, Ribeiro CA, Dias CC, Pestana MJ. Cost analysis of hemodialysis and peritoneal dialysis acess in incidente dialysis patients. Perit Dial Int. 2013; 33(6):662-70. doi: 10.3747/pdi.2011.00309.

Lamas J, Alonso M, Saavedra J, García-Trío G, Rionda M, Ameijeiras M. Costs of chornic dialysis in a public hospital: myths and realities. Nefrologia. 2001; 21(3):283-94.

Karopadi AN, Mason G, Rettore E, Ronco C. Cost of peritoneal dialysis and haemodialysis across the word. Nephorol Dial Transplant. 2013; 28(10):2553-69. doi: 10.1093/ndt/gft214.

Kirby L , Vale G. Dialysis for end-stage disease. Determining a cost-effective approach.Int J Technol Assess Care. 2001; 17(2): 181-9. doi: 10.1017/s0266462300105045.

Liu FX, Treharne C, Culleton B, Crowe L, Arici M. The financial impacto f increasing home-based high dose haemodialysis and peritoneal dialysis. BMC Nephrol. 2014;15:161. doi: 10.1186/1471-2369-15-161.

Treharne C, Liu FX, Arici M, Crowe L, Farooqui U. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective. Appl Health Econ Health Policy. 2014; 12(4):409-20. doi: 10.1007/s40258-014-0108-7

Li B, Cairns JA, Fotheringham J, Tomson CR, Forsythe JL, Watson C et al. Understanding costs of care for patients on renal replacement therapy: looking beyond fixed tariffs. Nephrol Dial Transplant. 2015; 30(10):1726-34. doi: 10.1093/ndt/gfv224

Salonen T, Reina T, Oksa H, Sintonen H, Pasternack A. Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis. 2003; 42(6):1228-38. doi: 10.1053/j.ajkd.2003.08.024.

Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis-a cost-utility analysis. Perit Dial Int. 2002; 22(1):39-47.

Johnson DW, Vincent K, Blizzard S, Rumpsfeld M, Just P. Cost savings from peritoneal dialysis therapy time extension using icodextrin. Adv perit Dial. 2003; 19:81-5.

Obiagwu PN, Abdu A.peritoneal dialysis vs. Haemodialysis in the management of paediatric acute kidney injury in Kano, Nigeria: a cost analysis. Trop med Int health. 2015; 20(1)2-7. doi: 10.1111/tmi.12409.

Atapour A, Eshaghian A, Taheri D, Dolatkhah S. Hemodialysis versus peritoneal dialysis, which is cost-effective? Saudi J Kidney Dis Transpl. 2015; 26(5):926-5. doi: 10.4103/1319-2442.164578

Roter RC. The cost barrier to renal replacement therapy and peritoneal dialysis in the developing world. Perit Dial Int. 2011; 21(3):314-317.

Cortés-Sanabria L, Rodríguez-Arreola BE, Ortiz-Juárez VR, Soto-Molina H, Pazarín-Villaseñor L, Martínez-Ramírez HR et al. Comparison of direct medical costs between automated and continuous ambulatory peritoneal dialysis. Perit Dial Int. 2013; 33(6):679-86. doi: 10.3747/pdi.2011.00274.

Pacheco A, Saffie A, Torres R, Tortella C, Llanos C, Vargas D et al. Cost/Utility study of peritoneal dialysis and hemodialysis in Chile. Perit Dial Int. 2007; 27(3):359-63.

Sancho LG, Dain S. Cost-effectiveness analysis of renal replacement therapies: how should we desing reserch on these interventions in Brazil? Cad Saúde Publica. 2018; 24(6):1279-90. doi:10.1590/s0102-311x2008000600009

Abreu MM, Walker DR, Sesso RC, Ferraz MB. A cost evalution of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in São Paulo, Brazil. Perit Dial Int. 2013; 33(3):304-15. doi: 10.3747/pdi.2011.00138.

Cherchiglia ML, Gomes IC, Alvares J, Guerra Júnior A, Acúrcio Fde A, Andrade EI et al. Determinants of expenditures on dialysis in the Unified National Health System, Brazil, 2000 to 2004. Cad Saude Publica. 2010; 26(8): 1627-41. doi: 10.1590/s0102-311x2010000800016.

Gouveia DSES, Bignelli NO , Hokazono SR , Danucalov eu , Siemens TA , Meyer F et al. Analysis of economic impact between the modality of renal replacement therapy. J Bras Nefrol. 2017; 39(2):162-71. doi: 10.5935/0101-2800.20170019.

Dratwa M. Costs of home assistance for peritoneal dialysis: results of a European survey. Kidney Int Suppl. 2008; (108):S72-5. doi: 10.1038/sj.ki.5002605.

Youssouf S, O'Donoghue D. Quality versus costs: a false paradigma. Perit Dial Int. 2014; 34(7):692-4. doi: 10.3747/pdi.2014.00220.

Buxton MJ, West RR. Cost-benefit analysis of long-term haemodialysis for chronic renal failure. Br Med J. 1975 ; 2(5967):376-9. doi:10.1136/bmj.2.5967.376.

Rose W, Grossöhmichen A. Dialysis costs. Wasrd-integrated dialysis. Z Urol Nephrol. 1979; 72(1):31-5.

Roberts SD, Maxwell DR, Gross TL. Cost-effective care of end-stage renal disease: a billion dolar question. Ann Intern Med. 1980; 92(2 pt 1):243-8. doi: 10.7326/0003-4819-92-2-243.

Ruchlin HS. The public cost of kidney disease. Soc Work Health Care. 1984; 9(4):1-9. doi: 10.1300/J010v09n04_01.

Shih YC, Guo A, Just PM, Mujais S. Imapct of initial dialysis modality and modality switxhes on medicare expenditures of end-stage renal disease patients. Kidney Int. 2005; 68(1):319-29. doi: 10.1111/j.1523-1755.2005.00413.x.

Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting-a multicentre study. Nephrol Dial Transplant. 2008; 23(6):1982-9. doi: 10.1093/ndt/gfm870.

Liu FX, Treharne C, Arici M, Culleton B. Hight dose demodialysis versus conventional in center hemodialysis: a cost-utilitary analysis from a UK payer perspective. Value health. 2015; 18(1):17-24. doi:10.1016/j.jval.2014010.002.

Liu FX, Walton SM, Leipold R, Isbell D, Golper TA. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system. Perit Dial Int. 2014; 34(7):749-57. doi: 10.3747/pdi.2013.00305

Yang F, Lau T, Luo N. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore. Nephrology. 2016; 21(8):669-77. doi: 10.1111/nep.12668.

Chang YT, Hwang JS, Hung SY, Tsai MS, Wu JL, Sung JM et al. Cost-effectiveness of hemodialysis and peritoneal dialysis: a national cohort study with 14 years follow-up and matched for comorbidities and propensity score. Sci Rep. 2016; 27(6):30266. doi: 10.1038/srep30266.

McFarlane PA, Pierratos A, Redelmeier DA. Cost savings of home nocturnal versus conventional in -center hemodialysis. Kidney Int. 62(2):2216-22. doi: 10.1046/j.1523-1755.2002.00678.x 10.1046/j.1523-1755.2002.00678.x.

Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A et al. Systematic review of the effectiveness and cost-effectiveness, and economic evalution, of home versus hospital or satellite unit haemodialysis for people with ens-stage renal failure. Health Technol Assess. 2003; 7(2):1-174.

Ploth DW, Shepp PH, Counts C, Hutchison F. Prospective analysis of global costs for maintenance of patients with ESRD. Am J Kidney Dis. 2003; 42(1):12-21. doi: 10.1016/s0272-6386(03)00404-9.

Gonzalez-Perez JG, Vale G, Stearns SC, Wordsworth S. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options. Int Technol Assess Health Care. 2005; 21(1):32-9. doi: 10.1017/s026646230505004x.

Grun RP, Constantinovici N, Normand C, Lamping DL. Costs of dialysis for elderly people in the UK. Nephrol Dial Transplant. 2003; 18(10):2122-7. doi: 10.1093/ndt/gfg354.

Chen B, Fan VY, Chou YJ, Kuo CC. Costs of care at the end of life among elderly patients with chronic kidney disease: patterns and predictors in a nation wide cohort study. BMC Nephrol. 2017; 18(1):36. doi: 10.1186/s12882-017-0456-2.

Grima DT, Bernard LM, Dunn ES, McFarlane PA, Mendelssohn DC. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics. 2012; 30(11):981-9. doi: 10.2165/11599390-000000000-00000.

Takura T. Coat-effectiveness of hemodialysis in Japan. Contrib Nephrol. 2015; 185:124-31. doi: 10.1159/000380976

Reilly R, Evans K, Gomersall J, Gorham G, Peters MD, Warren S. Effectiveness, cost effectiveness, acceptability and implementation barriers/enablers of chronic kidney disease management programs for Indigenous people in Australia, New Zealand and Canada: a systematic review of mixed evidence. BMC Health Serv Res. 2016; 6;16:119. doi: 10.1186/s12913-016-1363-0.

Gorham G, Howard K, Togni S, Lawton P, Hughes J, Majoni SW et al. Economic and quality of care evaluation of dialysis servisse models in remote Australia: a protocol for a mixed methods study. BMC Health Serv Res. 2017; 17(1):320. doi: 10.1186/s12913-017-2273-5.

Erek E, Sever MS, Akoglu E, Sariyar H, Bozfakioglu S, Apaydin S et al. Cost of renal replacement therapy in Turkey. Nephrology. 2004; 9(1):33-8.

Kleijn R, Uyl-de Groot C, Hagen C, Diepenbroek A, Pasker-de Jong P, Ter Wee P. Differences in care burden of patients undergoing dialysis in diferente centres in the netherlands. J Ren Care. 2017; 43(2):98-107. doi: 10.1111/jorc.12193.

Parra E, Arenas MD, Alonso M, Martínez MF, Gamen Á, Aguarón J et al. Assessing value-based health care delivery for haemodialysis. J Eval Clin Pract. 2017; 23(3):477-85. doi: 10.1111/jep.12483.

Wordsworth S, Ludbrook A. Comparing costing results in across contry economic evalutions: the use of technology specific purchasing power parities. Health Econ. 2005; 14(1):93-9. doi: 10.1002/hec.913.

Hirth RA. The organization and financing of kidney dialysis and transplant care in the United States of America. Int J Health Care Finance Econ. 2007; 7(4):301-18. doi: 10.1007/s10754-007-9019-6.

Turenne M, Baker R, Pearson J, Cogan C, Mukhopadhyay P, Cope E. Payment Reform and health disparities: changes in dialysis modality under the new Medicare dialysis payment system. Health Serv Res. 2018; 53(3):1430-57. doi: 10.1111/1475-6773.12713.

Lee CP, Zenios SA, Chertow GM. Cost-effectiveness of frequente in-center hemodialysis. J Am Soc Nephrol. 2008; 19(9):1792-7. doi: 10.1681/ASN.2008010001.

Icks A, Haastert B, Gandjour A, Chernyak N, Rathmann W, Giani G et. al. Costs of dialysis- a regional population-basec analysis. Nephrol Dial Transplant. 2010; 25(5):1647-52. doi: 10.1093/ndt/gfp672.

Parra Moncasi E, Arenas Jiménez MD, Alonso M, Martínez MF, Gámen Pardo A, Rebollo P et al. Multicentre study of haemodialysis costs. Nefrologia. 2011; 31(3):299-307. doi: 10.3265/Nefrologia.pre2011.Apr.10813.

Bavanandan S, Ahmad G, Teo AH, Chen L, Liu FX. Budget Impact analysis of peritoneal dialysis versus conventional In-center hemodialysis in Malásia. Value Health Reg Issues. 2016; 9:8-14. doi: 10.1016/j.vhri.2015.06.003

Khoe LC, Kristin E, Masytoh LS, Herlinawaty E, Werayingyong P et al. Economic evalution of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia. PLoS One. 2017; 12(5):e0177436. doi: 10.1371/journal.pone.0177436.

Upadhayay A, Susantitaphong, Jaber BL. Ultrapure versus standard dialysate: a cost-benefit analysis. Semin Dial. 2017; 30(5):398-402. doi:10.1111/sdi.12618.

Komenda P, Copland M, Makwana J, Djurdjev O, Sood MM, Levin A. The cost of starting and maintaining a large home hemodialysis program. Kidney Int. 2010; 77(11):1039-45. doi: 10.1038/ki.2010.37.

Kronborg C, Kjær T, Bech M. Cost analusis of establishing dialysis facilities for the treatment of chronic renal failure in Greenland. Int J Circumpolar Health. 2010; 69(5):470-9. doi: 10.3402/ijch.v69i5.17687.

Mahdavi-Mazdeh M, Zamani M, Zamyadi M, Rajolani H, Tajbakhsh K, Heidary Rouchi A et al. Hemodialysis cost in Tehran, Iran. Hemodial Int. 2008; 12(4):492-8. doi: 10.1111/j.1542-4758.2008.00313.x.

Arefzadeh A, Lessanpezeshki M, Seifi S. The costs of hemodialysis in Iran. Saudi J Kidney Dis Transpl. 2009; 20(2):307-11.

AL Saran K, Sabry A. The cost of hemodialysis in a large hemodialysis center. Saudi J Kidney Dis Transpl. 2012; 23(1):78-82.

Durán-Arenas L, Avila-Palomares PD, Zendejas-Villanueva R, Vargas-Ruiz MM, Tirado-Gómez LL, López-Cervantes M. Direct cost analysis of hemodialysis units. Salud Publica Mex. 2011; 53(4):516-24.

Cleemput I, Laet C. Analysis of the costs of dialysis and the effects of an incentive mechanism for low-cost dialysis modalities. Health Policy. 2013; 110(2-3):172-9. doi: 10.1016/j.healthpol.2013.03.001.

Naoum P, Topkaroglou I, Kitsonis D, Skroumpelos A, Athanasakis K, Iatrou C et al. Cost calculationd during “dire Straits”: a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece. Int J Artif Organs. 2016; 39(2):87-9. doi: 10.5301/ijao.5000477

Ahlawat R, Tiwari P, D'Cruz S. Direct cost for trearing chronic kidney disease at an outpatient setting of a tertiary hospital: evidence from a cross-sectional study. Value Health Reg Issues. 2017;12:36-40. doi: 10.1016/j.vhri.2016.10.003.

KouKou MG, Smyrniotis VE, Arkadopoulos NF, Grapsa EI. Pd vs HD in post-economic crisis Greece-differences in patient characteristics and estimation of therapy cost. Perit Dial Int. 2017; 37(5):568-73. doi: doi:10.3747/pdi.2016.00292.

Lee J, Lee JP, Park JI, Hwang JH, Jang HM, Choi JY et al. Early nephrology referral reduces the economic costs among patients who start renal replacement thehrapy: a prospective cohort study in Korea. Plos one. 2014; 9(6):e99460. doi: 10.1371/journal.pone.0099460.

Klarenbach SW, Tonelli M, Chui B, Manns BJ. Economic evalution of dialysis therapies. Nat Rev Nephrol. 2014; 10(11):644-52. doi: 10.1038/nrneph.2014.145.

Wang T, Abraham L, Akiba T, Blake P, Gokal R, Kim MJ et al. Peritoneal dialysis in asia in the 21st century: perspectives on and obstacles to peritoneal dialysis therapy in Asian countries. Perit Dial Int. 2002; 22(2):243-8.

Mushi L, Marschall P, Fleßa S. The cost of dialysis in low and middle-income countries: a systematic review. BMC Health Serv Res. 2015; 15:506. doi: 10.1186/s12913-015-1166-8.

Al-Shdaifat EA, Manaf MR. The economic burden of hemodialysis in Jordan. Indian J Med Sci. 2013; 67(5-6):103-16. doi: 10.4103/0019-5359.122734.

Gregory MC. Cost-effective dialysis for the developing world. Ethn Dis. 2009; 19(suppl 1):65-7.

Takemoto Y, Naganuma T. The economic issues of hemodialysis theraphy within the Japanese health care system. Contrib Nephrol. 2017; 189:257-261. doi:10.1159/000450819

Takura T, Kawanishi H, Minakuchi J, Nagake Y, Takahashi S. Cost-effectiveness analysis of on-line hemodiafiltration in Japan. Blood Purif. 2013; 35(1):85-9. doi: 10.1159/000346358.

Mazairac AH, Blankestijn PJ, Grooteman MP, Penne EL, Van Weerd NC, Hoedt CH et al. The cost-utility of haemodiasfiltration versus haemodialysis in the convective transport study. Nephrol Dial Transplant. 2013; 28(7):1865-73. doi: 10.1093/ndt/gft045.

Laplante S, Liu FX, Culleton B, Bernardo A, King D, Hudson P. The cost effectiveness of high-dose versus conventional haemodialysis: a systematic review. Appl Health Econ Health Policy. 2016; 14(2):185-93. doi: 10.1007/s40258-015-0212-3.

Beby AT, Cornelis T, Zinck R, Liu FX. Cost-effectiveness of high dose hemodialysus in comparison to conventional in-center hemodialysis in the netherlands. Adv Ther. 2016; 33(11):2032-48. doi: 10.1007/s12325-016-0408-4.

Tediosi F, Bertolini G, Parazzini F, Mecca G, Garattini L. Costs analysis of dialysis modalities in Italy. Health Serv Manage Res. 2001; 14(1):9-17. doi: 10.1177/095148480101400102.

Zambrowski JJ. Cost of dialysis in France. Nephrol Ther. 2016; 12(Suppl 1):95-7. doi: 10.1016/j.nephro.2016.02.002.

Ferguson TW, Tangri N, Rigatto C, Komenda P. Cost-effective treatment modalities for reducing morbidity associated with chronic Kidney diasease. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(2):243-52. doi: 10.1586/14737167.2015.1012069.

Younis M, Jabr S, Al-Khatib A, Forgione D, Hartmann M, Kisa A. A cost analysis of kidney replacement therapy options Palestine. Inquiry. 2015; 52:1-8. doi: 10.1177/0046958015573494.

Eriksson JK, Neovius M, Jacobson SH, Elinder CG, Hylander B. healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden. BMJ Open. 2016; 6(10):e012062. doi: 10.1136/bmjopen-2016-012062

Kim SH, Jo MW, Go DS, Ryu DR, Parque J. Economic burden of chronic kidney disease in Lorea using national sample cohort. J Nephrol. 2017; 30(6):787-93. doi: 10.1007/s40620-017-0380-3

Damien P, Lanham HJ, Parthasarathy M, Shah NL. Assessing key cost drivers associated with caring dor chronic kidney disease patients. BMC Health Serv Res. 2016; 16(1):690. doi: 10.1186/s12913-016-1922-4

Vaccaro CM, Sopranzi F. A comparison between the costs of dialysis treatment in Marche Region, Italy: Macerata and Tolentino hospitals. Ann Ist Super Sanita. 2017; 53(4):344-9. doi: 10.4415/ANN_17_04_12

Ferraresi H, Nazha H, Vigotti FN, Pereno A, Di Giorgio L, Gatti R et al. Ecodialysis: first strategies to limit damages and reduce cots. G Ital Nefrol. 2014; 31(5):1-6.

Menezes FG, Barreto DV, Abreu RM, Roveda F, Pecoits Filho RF. Overview of hemodialysis treatment funded by the Brazilian Unified Health System: Ann economic perspective. J Bras Nefrol. 2015; 37(3):367-78. doi: 10.5935/0101-2800.20150057

Lima AF. Direct cost of monitoring conventional hemodialysis conducted by nursing professionals. Rev Bras Enferm. 2017; 70(2):357-63. doi: 10.1590/0034-7167-2016-0447

Gonçalves GMR, Silva EN. Cost of chronic kidney disease attributable to diabetes from the perpective of the Brazilian Unified Health System. Plos One. 2018; 13(10):1-15. doi:10.1371/journal.pone.0203992

Publicado
2019-11-28
Como Citar
Schreider, A., de Souza Neto, M. F., Paula Pereira, J., & Maria da Silva Fernandes, N. (2019). Estudos de custo sobre terapia dialítica no mundo: uma revisão sistemática e uma abordagem histórica. HU Revista, 45(3), 312-334. https://doi.org/10.34019/1982-8047.2019.v45.28663
Seção
Artigos de Revisão Sistemática